The Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1006171

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The BLOCADE Feasibility Study aims to find out what is needed for a study to see if the drug carvedilol reduces heart disease events in people who need kidney dialysis. Carvedilol is widely used to treat the types of heart disease that are common in people on dialysis but the nature of dialysis may lead to more side effects or to less benefit. A Feasibility Study must be done first to properly plan a large study of carvedilol in people on dialysis that answers this important question.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2015

Funding Scheme: Project Grants

Funding Amount: $597,811.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Nephrology and Urology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cardiovascular disease | cardiovascular pharmacology | randomised controlled trial (RCT) | renal dialysis

Related Links